The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: Results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance) Academic Article uri icon

Overview

MeSH Major

  • Androgen Antagonists
  • Antineoplastic Combined Chemotherapy Protocols
  • Bone Neoplasms
  • Liver Neoplasms
  • Lung Neoplasms
  • Prostatic Neoplasms

abstract

  • As measured by OS, PFS, PSA, and the ORR, there was no evidence that prior treatment with ketoconazole had an impact on the clinical outcomes of patients with mCRPC who received subsequent docetaxel-based therapy. The current results highlight the need for prospective studies to assess for potential cross-resistance with novel ASIs and to define the optimal sequence of therapy in mCRPC.

publication date

  • October 15, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3795898

Digital Object Identifier (DOI)

  • 10.1002/cncr.28285

PubMed ID

  • 23913744

Additional Document Info

start page

  • 3636

end page

  • 43

volume

  • 119

number

  • 20